[Clinical outcomes of 31 patients with acute leukemia receiveing modified conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation].
作者信息
Shi Y Y, Zhang G X, He Y, Han M Z, Feng S Z, Zhang R L, Jiang E L
机构信息
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):763-767. doi: 10.3760/cma.j.issn.0253-2727.2021.09.009.
Abstract
摘要
相似文献
1
[Clinical outcomes of 31 patients with acute leukemia receiveing modified conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation].31例接受含克拉屈滨改良预处理方案的急性白血病患者自体造血干细胞移植的临床结局
Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):763-767. doi: 10.3760/cma.j.issn.0253-2727.2021.09.009.
2
Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia.克拉屈滨联合白消安和环磷酰胺作为复发或难治性急性髓系白血病异基因造血干细胞移植前强化预处理方案的疗效和安全性。
Transpl Immunol. 2024 Jun;84:102037. doi: 10.1016/j.trim.2024.102037. Epub 2024 Mar 16.
3
[Efficacy and Safety of Cladribine-based Intensified Conditioning Regimen in Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia].基于克拉屈滨的强化预处理方案在高危急性髓系白血病患者造血干细胞移植中的疗效与安全性
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):65-71. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.011.
4
[Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen].含克拉屈滨方案的异基因造血干细胞移植治疗12例难治/复发急性髓系白血病的临床观察
Zhonghua Xue Ye Xue Za Zhi. 2019 Oct 14;40(10):827-830. doi: 10.3760/cma.j.issn.0253-2727.2019.10.006.
5
Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.
Transplant Proc. 2005 Dec;37(10):4482-7. doi: 10.1016/j.transproceed.2005.10.100.
6
Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.含克拉屈滨和地西他滨的预处理方案在复发或难治性急性髓系白血病及高危骨髓增生异常综合征患者中移植后复发率较低。
Int J Cancer. 2023 May 15;152(10):2123-2133. doi: 10.1002/ijc.34419. Epub 2023 Jan 13.
7
[Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].[采用FLAG序贯白消安/环磷酰胺预处理方案进行异基因造血干细胞移植治疗难治/复发急性髓系白血病的临床结局]
Zhonghua Nei Ke Za Zhi. 2018 Aug 1;57(8):576-581. doi: 10.3760/cma.j.issn.0578-1426.2018.08.008.
8
A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.一种针对难治性或复发性急性髓系白血病患者进行异基因造血干细胞移植的新型强化预处理方案。
Medicine (Baltimore). 2018 Apr;97(17):e0228. doi: 10.1097/MD.0000000000010228.
9
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.急性白血病患者 HLA 全相合同胞异基因造血干细胞移植中，减低剂量预处理方案与清髓性预处理方案的比较结果：单中心经验
Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8.
10
Autologous Hematopoietic Recovery after Unrelated Umbilical Cord Blood Transplantation with Myeloablative Conditioning for Acute Myelogenous Leukemia.异基因脐带血造血干细胞移植预处理方案对急性髓系白血病患者的造血重建影响
Intern Med. 2020 Oct 1;59(19):2409-2414. doi: 10.2169/internalmedicine.4829-20. Epub 2020 Jun 15.
引用本文的文献
1
[Chinese consensus on autologous stem cell transplantation for adult acute leukemia (2024)].《成人急性白血病自体造血干细胞移植中国专家共识（2024年版）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):637-644. doi: 10.3760/cma.j.cn121090-20240611-00218.
本文引用的文献
1
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.急性髓系白血病患者可测量残留病的当前治疗策略。
Cancer. 2019 Sep 15;125(18):3121-3130. doi: 10.1002/cncr.32354. Epub 2019 Jul 10.
2
The emerging role of measurable residual disease detection in AML in morphologic remission.在形态缓解的 AML 中，可测量残留疾病检测的新兴作用。
Semin Hematol. 2019 Apr;56(2):125-130. doi: 10.1053/j.seminhematol.2018.09.001. Epub 2018 Sep 19.
3
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.在首次完全分子缓解的费城阳性急性淋巴细胞白血病成人患者中，自体和同种异体造血干细胞移植的可比结果：来自 EBMT 急性白血病工作组的分析。
Eur J Cancer. 2018 Jun;96:73-81. doi: 10.1016/j.ejca.2018.03.018. Epub 2018 Apr 18.
4
Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.CLAG 与 FLAG 诱导化疗治疗复发/难治性急性髓系白血病的临床缓解率和生存比较：一项前瞻性队列研究。
Clin Transl Oncol. 2018 Jul;20(7):870-880. doi: 10.1007/s12094-017-1798-8. Epub 2017 Nov 27.
5
Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.急性髓系白血病（AML）自体造血干细胞移植（AHSCT）的长期结局——单中心回顾性分析
Pathol Oncol Res. 2018 Jul;24(3):469-475. doi: 10.1007/s12253-017-0266-7. Epub 2017 Jun 28.
6
Autologous hematopoietic stem cell transplantation for acute myeloid leukemia - single center experience.自体造血干细胞移植治疗急性髓系白血病——单中心经验。
Neoplasma. 2017;64(5):738-744. doi: 10.4149/neo_2017_512.
7
Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.细胞遗传学分类与微小残留病状态的联合与首次缓解的原发性急性髓系白血病成人患者自体与异基因干细胞移植的结局相关。
Leuk Res. 2017 Apr;55:97-104. doi: 10.1016/j.leukres.2017.01.026. Epub 2017 Jan 24.
8
Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.对于65岁以上的急性髓系白血病患者，首次缓解期进行自体干细胞移植巩固治疗是安全有效的。
Leuk Res. 2017 Feb;53:28-34. doi: 10.1016/j.leukres.2016.12.001. Epub 2016 Dec 8.
9
Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.自体干细胞移植对于低危和中危急性髓系白血病（AML）患者而言仍是一种有效的选择：一项针对809例首次完全缓解后接受自体移植患者的GITMO调查。
Bone Marrow Transplant. 2017 Jan;52(1):163-166. doi: 10.1038/bmt.2016.233. Epub 2016 Sep 26.
10
Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.多基因可测量残留病评估改善自体造血细胞移植中急性髓系白血病的复发风险分层
Biol Blood Marrow Transplant. 2016 Nov;22(11):1974-1982. doi: 10.1016/j.bbmt.2016.08.014. Epub 2016 Aug 17.
Zotero 插件